Sakar Healthcare Ltd

AI
Sakar Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Sakar Healthcare Ltd

₹ 890 -6.51%
23 Oct - close price
sakarhealthcare.com NSE: SAKAR
About

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]

Key Points

Business Overview:[1][2][3]
SHL, certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and the National Drug Authority, provides comprehensive healthcare and pharmaceutical products. Operating in over 50 countries with 292 registered products and 210 more under registration, SHL partners with 70+ overseas distributors. The company also engages in contract manufacturing for leading domestic brands and direct sales in both domestic and export markets.

Website NSE
  • Market Cap ₹ 1,980 Cr.
  • Current Price ₹ 890
  • High / Low ₹ 1,230 / 352
  • Stock P/E 46.2
  • Book Value ₹ 156
  • Dividend Yield 0.00 %
  • ROCE 12.4 %
  • ROE 9.99 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 23.1% CAGR over last 5 years
  • Company's median sales growth is 18.0% of last 10 years

Cons

  • Stock is trading at 5.72 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -0.82%
  • Company has a low return on equity of 7.49% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
34 37 43 41 43 43 50 53 58 70 71 73 87
25 28 32 30 31 32 35 40 46 52 45 52 63
Operating Profit 9 9 11 11 12 12 16 13 11 19 26 21 24
OPM % 27% 24% 25% 26% 27% 27% 31% 24% 20% 26% 37% 29% 28%
1 0 1 0 0 0 0 0 1 1 0 2 0
Interest 2 2 2 1 2 1 4 2 2 2 2 2 2
Depreciation 4 4 5 5 5 5 5 6 6 6 6 7 7
Profit before tax 4 3 5 5 5 5 6 5 5 11 18 15 16
Tax % 13% 31% 35% 49% 6% 17% 8% 13% 15% 6% 39% 29% 29%
4 2 3 2 5 5 6 5 5 10 11 10 11
EPS in Rs 1.70 0.95 1.43 1.11 2.21 2.06 2.62 2.10 2.04 4.61 4.95 4.62 5.08
Raw PDF
Upcoming result date: today

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
35 41 44 53 68 83 95 128 133 153 178 251 302
27 33 34 40 51 63 72 99 100 115 128 182 211
Operating Profit 8 8 10 13 17 20 23 29 33 38 50 69 90
OPM % 22% 20% 23% 24% 25% 24% 24% 23% 25% 25% 28% 27% 30%
0 0 1 0 1 2 1 2 5 3 1 2 2
Interest 3 3 3 3 2 2 2 3 6 8 9 8 8
Depreciation 2 3 3 4 6 7 8 10 15 18 21 24 25
Profit before tax 2 3 5 6 9 12 13 19 17 16 22 40 60
Tax % 24% 22% 30% 38% 28% 21% 19% 20% 24% 27% 19% 23%
2 2 3 4 7 10 11 15 13 12 18 30 43
EPS in Rs 2.30 2.78 3.08 3.12 4.47 6.43 6.84 8.90 6.70 5.37 7.97 13.70 19.26
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 20%
5 Years: 22%
3 Years: 24%
TTM: 48%
Compounded Profit Growth
10 Years: 30%
5 Years: 23%
3 Years: 34%
TTM: 119%
Stock Price CAGR
10 Years: %
5 Years: 42%
3 Years: 36%
1 Year: 145%
Return on Equity
10 Years: 9%
5 Years: 8%
3 Years: 7%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 8 8 11 12 15 15 16 17 19 22 22 22 22
Reserves 7 11 25 39 57 66 83 110 154 241 264 302 324
25 22 24 11 11 17 43 93 119 79 86 71 46
11 10 11 18 15 17 37 47 44 47 43 86 124
Total Liabilities 50 51 71 81 97 115 178 268 336 389 415 481 516
36 37 49 53 64 66 69 205 267 314 309 326 334
CWIP 0 0 0 0 9 13 49 1 6 0 17 4 6
Investments 0 0 0 0 0 0 0 7 3 0 0 0 0
14 14 22 28 25 36 60 55 60 74 90 151 176
Total Assets 50 51 71 81 97 115 178 268 336 389 415 481 516

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
4 9 2 5 16 19 15 36 33 24 34 49
-1 -4 -14 -8 -25 -22 -47 -90 -74 -52 -31 -28
-3 -6 13 -13 9 3 32 55 41 27 -3 -21
Net Cash Flow 1 -1 0 -16 0 -0 -0 -0 0 0 -0 -0
Free Cash Flow 4 5 -13 -4 -9 -4 -32 -62 -49 -35 2 21
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 60% 117% 30% 51% 104% 110% 67% 121% 113% 72% 73% 77%

Ratios

Standalone / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 21 26 44 74 51 36 48 40 60 50 63 73
Inventory Days 142 107 114 51 70 92 112 69 76 121 193 207
Days Payable 20 66 51 57 41 46 141 149 129 120 93 153
Cash Conversion Cycle 143 67 107 68 80 83 19 -39 7 51 163 127
Working Capital Days 27 10 67 98 31 31 2 -11 -6 29 52 45
ROCE % 14% 14% 15% 14% 16% 16% 13% 12% 9% 7% 9% 12%

Insights

In beta
Mar 2016 Dec 2018 Oct 2022 Mar 2024 Mar 2025 Mar 2026
Country Presence (Cumulative)
count

Log in to view insights

Please log in to see hidden values.

Login
Overseas/International Partners (Cumulative)
count
Oncology Dossiers Filed/Submitted (Cumulative)
count
Oncology Products/Molecules Developed (Cumulative)
count
Oncology Revenue Share
% of total revenue
Oncology Business Contracts Signed (Cumulative)
count
Oncology Marketing Authorizations (MAs) Received (Cumulative)
count
Oncology Plant Capacity Utilization
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

7 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
53.15% 53.15% 53.15% 53.15% 53.58% 53.58% 52.86% 52.86% 52.86% 52.86% 52.52% 51.70%
13.76% 13.52% 13.52% 13.42% 13.58% 13.61% 13.41% 13.31% 13.05% 12.94% 12.13% 12.34%
10.62% 10.62% 10.62% 10.62% 10.88% 10.97% 11.25% 11.43% 11.36% 11.32% 11.37% 11.92%
22.47% 22.71% 22.71% 22.80% 21.96% 21.85% 22.48% 22.41% 22.73% 22.87% 23.98% 24.04%
No. of Shareholders 7,0017,3867,3137,8678,5988,6088,1157,5657,0699,58014,73419,539

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls